U.S. patent application number 15/338302 was filed with the patent office on 2017-03-09 for transdiscal administration of specific inhibitors of pro-inflammatory cytokines.
The applicant listed for this patent is DePuy Synthes Products, LLC. Invention is credited to Mohamed Attawia, Scott Bruder, Thomas M. DiMauro, Sudhakar Kadiyala, Hassan Serhan, David Urbahns.
Application Number | 20170065641 15/338302 |
Document ID | / |
Family ID | 36923759 |
Filed Date | 2017-03-09 |
United States Patent
Application |
20170065641 |
Kind Code |
A1 |
Attawia; Mohamed ; et
al. |
March 9, 2017 |
Transdiscal Administration of Specific Inhibitors of
Pro-Inflammatory Cytokines
Abstract
The present invention relates to injecting a high specificity
cytokine antagonist into a diseased intervertebral disc.
Inventors: |
Attawia; Mohamed; (Holmdel,
NJ) ; DiMauro; Thomas M.; (Southboro, MA) ;
Serhan; Hassan; (South Easton, MA) ; Kadiyala;
Sudhakar; (Newton, MA) ; Urbahns; David;
(Barrington, RI) ; Bruder; Scott; (Franklin Lakes,
NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
DePuy Synthes Products, LLC |
Raynham |
MA |
US |
|
|
Family ID: |
36923759 |
Appl. No.: |
15/338302 |
Filed: |
October 28, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14220273 |
Mar 20, 2014 |
|
|
|
15338302 |
|
|
|
|
12291378 |
Nov 7, 2008 |
8728523 |
|
|
14220273 |
|
|
|
|
11881926 |
Jul 30, 2007 |
|
|
|
12291378 |
|
|
|
|
10456948 |
Jun 6, 2003 |
7344716 |
|
|
11881926 |
|
|
|
|
60470098 |
May 13, 2003 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/0012 20130101;
A61K 38/363 20130101; A61K 39/395 20130101; A61K 38/1793 20130101;
A61K 45/06 20130101; A61B 5/055 20130101; A61K 38/1875 20130101;
A61K 38/20 20130101; A61P 19/00 20180101; C12Y 304/21005 20130101;
A61K 9/0085 20130101; A61K 38/1841 20130101; A61K 35/28 20130101;
A61K 38/17 20130101; A61K 38/4833 20130101; A61K 38/18 20130101;
G01N 33/6869 20130101; A61K 39/3955 20130101; A61K 35/32 20130101;
A61B 17/7061 20130101; A61K 9/0019 20130101; G01N 2333/54 20130101;
A61K 47/34 20130101 |
International
Class: |
A61K 35/28 20060101
A61K035/28; A61K 9/00 20060101 A61K009/00; A61K 38/18 20060101
A61K038/18 |
Claims
1.-20. (canceled)
21. A method of inhibiting degeneration of an extracellular matrix
of a nucleus pulposus of an intervertebral disc having a
degenerating nucleus pulposus and an annulus fibrosus in a patient
in need thereof, comprising transdiscally administering into the
degenerating nucleus pulposus an effective amount of a formulation
comprising: viable allogenic mesenchymal stem cells in a
concentrated form, wherein the cells were obtained from bone marrow
and concentrated by centrifugation, filtration or
immunoabsorption.
22. The method of claim 21, wherein the cells administered into the
degenerating nucleus pulposus are cultured cells.
23. The method of claim 21, wherein the cells were obtained from
bone marrow and concentrated by centrifugation.
24. The method of claim 21, wherein the cells were obtained from
bone marrow and concentrated by filtration.
25. The method of claim 21, wherein the cells were obtained from
bone marrow and concentrated by immunoabsorption.
26. The method of claim 21, wherein the formulation is injected
into the nucleus pulposus of the intervertebral disc.
27. The method of claim 21, wherein the formulation is also
administered into the annulus fibrosus of the intervertebral
disc.
28. The method of claim 21, wherein the formulation is delivered in
a sustained release device.
29. The method of claim 28, wherein the sustained release device
comprises a polymer.
30. The method of claim 29, wherein the polymer is a bioresorbable
polymer.
31. The method of claim 29, wherein the polymer is selected from
the group consisting of polylactic acid (PLA), polyglycolic acid
(PGA), and polycaprolactone (PCL), or mixtures thereof.
32. The method of claim 28, wherein the sustained release device
comprises a biosensor.
33. The method of claim 21, further comprising transdiscally
administering a growth factor into the degenerating nucleus
pulposus.
34. The method of claim 33, wherein the growth factor is
transforming growth factor beta (TGF-.beta.) or a bone
morphogenetic protein (BMP).
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/220,273, filed Mar. 20, 2014, which is a continuation of
U.S. application Ser. No. 12/291,378, filed Nov. 7, 2008, now U.S.
Pat. No. 8,728,523, issued May 20, 2014, which is a continuation of
U.S. application Ser. No. 11/881,926, filed Jul. 30, 2007, now
abandoned, which is a Divisional of U.S. application Ser. No.
10/456,948, filed Jun. 6, 2003, now U.S. Pat. No. 7,344,716, issued
Mar. 18, 2008, which claims the benefit of U.S. Provisional
Application No. 60/470,098, filed May 13, 2003. The entire
teachings of the above applications are incorporated herein by
reference.
BACKGROUND OF THE INVENTION
[0002] The natural intervertebral disc contains a jelly-like
nucleus pulposus surrounded by a fibrous annulus fibrosus. Under an
axial load, the nucleus pulposus compresses and radially transfers
that load to the annulus fibrosus. The laminated nature of the
annulus fibrosus provides it with a high tensile strength and so
allows it to expand radially in response to this transferred
load.
[0003] In a healthy intervertebral disc, cells within the nucleus
pulposus produce an extracellular matrix (ECM) containing a high
percentage of proteoglycans. These proteoglycans contained sulfated
functional groups that retain water, thereby providing the nucleus
pulposus within its cushioning qualities. These nucleus pulposus
cells may also secrete small amounts of cytokines as well as matrix
metalloproteinases ("MMPs"). These cytokines and MMPs help regulate
the metabolism of the nucleus pulposus cells.
[0004] In some instances of disc degeneration disease (DDD),
gradual degeneration of the intervetebral disc is caused by
mechanical instabilities in other portions of the spine. In these
instances, increased loads and pressures on the nucleus pulposus
cause the cells to emit larger than normal amounts of the
above-mentioned cytokines. In other instances of DDD, genetic
factors, such as programmed cell death, or apoptosis can also cause
the cells within the nucleus pulposus to emit toxic amounts of
these cytokines and MMPs. In some instances, the pumping action of
the disc may malfunction (due to, for example, a decrease in the
proteoglycan concentration within the nucleus pulposus), thereby
retarding the flow of nutrients into the disc as well as the flow
of waste products out of the disc. This reduced capacity to
eliminate waste may result in the accumulation of high levels of
toxins.
[0005] As DDD progresses, the toxic levels of the cytokines present
in the nucleus pulposus begin to degrade the extracellular matrix
(in particular, the MMPs (under mediation by the cytokines) begin
cleaving the water-retaining portions of the proteoglycans, thereby
reducing its water-retaining capabilities). This degradation leads
to a less flexible nucleus pulposus, and so changes the load
pattern within the disc, thereby possibly causing delamination of
the annulus fibrosus. These changes cause more mechanical
instability, thereby causing the cells to emit even more cytokines,
thereby upregulating MMPs. As this destructive cascade continues
and DDD further progresses, the disc begins to bulge ("a herniated
disc"), and then ultimately ruptures, causing the nucleus pulposus
to contact the spinal cord and produce pain.
[0006] Olmarker, Spine 26(8), 2001, pp. 863-9("Olmarker I") and
Aoki, Spine 27(15), 2002, pp. 1614-17 teach that TNF-.alpha.
appears to play a role in producing the pain associated with the
nucleus pulposus contacting nerve roots of the spinal cord.
[0007] US Published Patent Application No. US 2003/0039651
("Olmarker II") teaches a therapeutic treatment of nerve disorders
comprising administration of a therapeutically effective dosage of
at least two substances selected from the group consisting of TNF
inhibitors (both specific and non-specific), IL-1 inhibitors, IL-6
inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors,
and IFN-gamma inhibitors.
[0008] In the examples of Olmarker II, Olmarker II further teaches
that these substances are to be administered through systemic
pathways. In particular, Olmarker II teaches that "the major
contribution of TNF-alpha may be derived from recruited, aggregated
and maybe even extravasated leukocytes, and that successful
pharmacologic block may be achieved only by systemic treatment.
[0133]. Of note, Olmarker II appears to discourage the local
addition of one therapeutic agent (doxycycline) to a transplanted
nucleus pulposus. [0128].
[0009] PCT Published Patent Application No. WO 02/100387 ("Olmarker
III") teaches the prevention of neovasculariation and/or
neo-innervation of intervertebral discs by the administration of
anti-angiogenic substances. Again, however, Olmarker III teaches
systemic administration of these therapeutic agents.
[0010] U.S. Pat. No. 6,419,944 ("Tobinick") discloses treating
herniated discs with cytokine antagonists, including infliximab.
However, Tobinick teaches that local administration involves a
subcutaneous injection near the spinal cord. Accordingly, Tobinick
does not teach a procedure involving a sustained delivery of a drug
for the treatment of DDD, nor directly administering a specific
cytokine antagonist (such as infliximab) into the disc.
[0011] US Published Patent Application No. 2003/0049256 (Tobinick
II) discloses that injection of such therapeutic molecules to the
anatomic area adjacent to the spine is accomplished by interspinous
injection, and preferably is accomplished by injection through the
skin in the anatomic area between two adjacent spinous processes of
the vertebral column.
[0012] Tobinick II further teaches that TNF antagonists may be
administered by interspinous injection in the human and that the
dosage level is in the range of 1 mg to 300 mg per dose, with
dosage intervals as short as two days. Tobinick II further
discloses that Interleukin-1 antagonists are administered in a
therapeutically effective dose, which will generally be 10 mg to
200 mg per dose, and their dosage interval will be as short as once
daily.
[0013] Tobinick, Swiss Med. Weekly, 2003, 133, 170-77 ("Tobinick
III") teaches both perispinal and epidural administration of TNF
inhibitors for spine related therapies.
[0014] Karppinen, Spine, 28(8), 203, pp. 750-4, teaches
intravenously injecting or orally administering infliximab into
patients suffering from sciatica.
[0015] As with Tobinick I and II, Karppinen does not teach a
procedure involving a sustained delivery of a drug for the
treatment of DDD, nor directly administering a specific cytokine
antagonist (such as infliximab) into the disc.
[0016] U.S. Pat. No. 6,352,557 (Ferree) teaches adding therapeutic
substances such as anti-inflammatory medications to morselized
extra-cellular matrix, and injecting that combination into an
interverterbral disc.
[0017] However many anti-inflammatory agents are non-specific and
therefore may produce unwanted side effects upon other cells,
proteins and tissue. In addition, the pain-reducing effect of these
agents is typically only temporary. Lastly, these agents typically
only relieve pain, and are neither curative nor restorative.
[0018] Alini, Eur. Spine J. 11(Supp.2), 2002, pp. S215-220, teaches
therapies for early stage DDD, including injection of inhibitors of
proteolytic enzymes or biological factors that stimulate cell
metabolic activity (i.e., growth factors) in order to slow down the
degenerative process. Alini I does not disclose inhibiting growth
factors.
[0019] US Published Patent Application US 2002/0026244 ("Trieu")
discloses an intervertebral disc nucleus comprising a hydrogel that
may deliver desired pharmacological agents. Trieu teaches that
these pharmacological agents may include growth factors such as
TGF-B and anti-inflammatory drugs, including steroids. Trieu
further teaches that these pharmacological agents may be dispersed
within the hydrogel having an appropriate level of porosity to
release the pharmacological agent at a desired rate. Trieu teaches
that these agents may be released upon cyclic loading or upon
resorption.
[0020] Takegami, Spine, 27(12), 2002, 1318-25 teaches that
injecting TGF-B into the disc space results in enhanced
replenishment of the extracellular matrix damaged by cytokines.
Takegami further teaches that the half-life of a growth factor
injected into the interveterbal disc can be expected to be longer
than that injected into a synovial joint because the nucleus
pulposus is surrounded by the fibrous structure of the annulus
fibrosus, thus providing a confined environment. Diwan, Tissue
Engineering in Orthopedic Surgery, 31(3) July 2000, pp. 453-464,
reports on another Takegami paper that concluded that a delivery
system allowing prolonged delivery (>3 days) would have to be
used to obtain the observed effect of the growth factor.
[0021] Alini, Spine 2003 28(5), pp. 446-54, discloses a cell seeded
collagen-hyaluronan scaffold supplemented with growth factors such
as TGF-B, bFGF, and IGF-1 for use in regenerating a nucleus
pulposus.
[0022] Maeda et al. Spine 2000, 25(20 pp. 166-169, 2000 reports on
the in vitro response to interleukin-1 receptor antagonist protein
(IRAP) of rabbit annulus fibrosus exposed to IL-1. Maeda suggests
that TRAP could be useful in inhibiting the degradation of the
disc.
[0023] Yabuki, Spine, 2001, 26(8), 870-5, teaches the use of an
anti-TNF drug for the treatment of sciatica.
[0024] U.S. Pat. No. 6,277,969 ("Le") discloses the use of anti-TNF
antibodies for therapy of TNF-mediated pathologies. Le teaches
parental administration of the antibodies.
[0025] In sum, when investigators suggest the administration of
specific TNF-a inhibitors or specific interleukin inhibitors, the
investigators appear not only to teach only the administration of
those therapeutics to tissue outside the disc, but it also appears
to discourage the trans-discal administration of therapeutic
substances.
SUMMARY OF THE INVENTION
[0026] The present inventors have developed a number of procedures
for efficaciously treating degenerative disc disease by drug
therapy.
[0027] The present inventors have noted that although Tobinick,
Olmarker and Karppinenen taught the therapeutic use of
pro-inflammatory cytokine-antagonist monoclonal antibodies in
treating sciatica, each of these investigators targeted tissue
outside of the disc.
[0028] In accordance with the present invention, the present
inventors have developed a method of treating an intervertebral
disc in which a high specificity inhibitor of a pro-inflammatory
cytokine is administered transdiscally (i.e., the target tissue is
a degenerating disc).
[0029] There are believed to be several advantages to directly
administering these therapeutic inhibitors to a targeted disc over
the treatments disclosed by Tobinick and Karppinenen:
[0030] First, since it is known that many cytokines (such as
interleukins and TNF-.alpha.) also play roles in mediating the
degradation of the extracellular matrix (ECM) of the nucleus
pulposus, injecting an antagonist or inhibitor of these proteins
directly into the disc prevents the target cytokine from inducing
any further ECM degradation. In effect, the transdiscal
administration of the cytokine antagonist arrests the aging process
of the degenerating disc. Accordingly, the present invention seeks
to treat the degenerative disc at a much earlier stage of DDD than
Tobinick and Karppinenen and thereby prevents degradation of the
ECM.
[0031] Second, it is further known that nerve ending nociceptors
are present within the annulus fibrosus, and that cytokines such as
TNF irritate nerves. It is believed that injecting an anti-TNF
antagonist into the disc space also prevents the TNF from causing
nerve irritation within the disc. Thus, the pain attributed to
irritation of these nerves can be efficiently eliminated.
[0032] Third, since the annulus fibrosus portion of the disc
comprises a relatively dense fibrosus structure, this outer
component of the disc may provide a suitable depot for the high
specificity cytokine antagonist (HSCA), thereby increasing its
half-life in the disc.
[0033] Fourth, since the high specificity antagonist inhibits only
the specific cytokine of interest, the HSCA may be combined with
other therapeutic agents (such as TGF-B, or mesenchymal stem cells)
that can also be injected into the disc without reducing the
effectiveness of those agents.
[0034] Fifth, since it is believed that many of the problematic
cytokines are actually secreted by either nucleus pulposus or
annulus fibrosus cells, transdiscal injection of the high
specificity antagonists will advantageously attack the problematic
cytokines at their source of origination.
[0035] Accordingly, in a first aspect of the present invention,
there is provided a method of treating an intervertebral disc
having a nucleus pulposus, comprising the steps of:
[0036] a) transdiscally administering a formulation comprising a
high specificity cytokine antagonist (HSCA) into an intervertebral
disc.
DETAILED DESCRIPTION OF THE INVENTION
[0037] A description of preferred embodiments of the invention
follows.
[0038] For the purposes of the present invention, the terms
"inhibitor" and antagonist" are used interchangeably. A protein may
be inhibited at the synthesis level, at the translation level, by
shedding, by antibodies, or by soluble receptors. The term
"patient" refers to a human having a degenerating disc.
[0039] For the purposes of the present invention "Transdiscal
administration" includes, but is not limited to:
[0040] a) injecting a formulation into the nucleus pulposus of a
degenerating disc, preferably a relatively intact degenerating
disc,
[0041] b) injecting a formulation into the annulus fibrosus of a
degenerating disc, preferably relatively intact degenerating
disc.
[0042] c) providing the formulation in a patch attached to the
outer wall of the annulus fibrosus,
[0043] d) providing the formulation in a depot at a location
outside but closely closely adjacent the outer wall of the annulus
fibrosus (hereinafter, "trans-annular administration".
[0044] e) providing the formulation in a depot at a location
outside but closely adjacent the endplates of the adjacent
vertebral bodies (hereinafter, "trans-endplate administration".
[0045] Because DDD is a continuous process, the degenerating disc
to which the therapeutic drug is administered may be in any one of
a number of degenerative states. Accordingly, the degenerating disc
may be an intact disc. The degenerating disc may be a herniated
disc (wherein a portion of the annulus fibrosus has a bulge). The
degenerating disc may be a ruptured disc (i.e., wherein the annulus
fibrosus has ruptured and bulk nucleus pulposus has exuded). The
degenerating disc may be delaminated (wherein adjacent layers of
the annulus fibrosus have separated). The degenerating disc may
have fissures (wherein the annulus fibrosus has fine cracks or
tears through which selected molecules from the nucleus pulposus
can leak).
[0046] The present invention is directed to providing directly
through a diseased intervertebral disc at least one highly specific
cytokine antagonist capable of specifically inhibiting a cytokine
(preferably, a pro-inflammatory cytokine) present in the disc.
Preferably, the HSCA inhibits the action of a specific
pro-inflammatory cytokine released by disc cells or by invading
macrophages during the degenerative process.
[0047] In some embodiments, the antagonist is capable of
specifically inhibiting a pro-inflammatory cytokine selected from
the group consisting of TNF-.alpha., an interleukin (preferably,
IL-1, Il-6 and IL-8), phospholipase A2 (PLA2), FAS, an FAS ligand,
and IFN-gamma. Such specific inhibitors include those identified on
pages 5-18 of Olmarker II, the specification of which is
incorporated by reference in its entirety.
[0048] In some embodiments, the HSCA inhibits the cytokine by
preventing its production. In some embodiments, the HSCA inhibits
the cytokine by binding to a membrane-bound cytokine. In others,
the HSCA inhibits the cytokine by binding to a solubilized
cytokine. In some embodiments, the HSCA inhibitor inhibits the
cytokine by both binding to membrane bound cytokines and to
solubilized cytokine. In some embodiments, the HSCA is a monoclonal
antibody ("mAb"). The use of mAbs is highly desirable since they
bind specifically to a certain target protein and to no other
proteins. In some embodiments, the HSCA inhibits the cytokine by
binding to a natural receptor of the target cytokine.
[0049] In some embodiments, the HSCA inhibits the cytokine by
preventing its production. One example thereof is an inhibitor of
p38 MAP kinase. In some embodiments, the TNF inhibitor inhibits the
TNF by binding to membrane bound TNF in order to prevent its
release from membrane. In others, the TNF inhibitor inhibits the
TNF by binding to solubilized TNF. One example thereof is
etanercept. In some embodiments, the TNF inhibitor inhibits the TNF
by both binding to membrane bound TNF and to solubilized TNF. One
example thereof is infliximab. In some embodiments, the HSCA
inhibits the cytokine by binding to a natural receptor of the
target cytokine.
[0050] Preferred TNF antagonists include, but are not limited to
the following: etanercept (Enbrel.RTM.-Amgen); infliximab
(Remicade.RTM.-Johnson and Johnson); D2E7, a human anti-TNF
monoclonal antibody (Knoll Pharmaceuticals, Abbott Laboratories);
CDP 571 (a humanized anti-TNF IgG4 antibody); CDP 870 (an anti-TNF
alpha humanized monoclonal antibody fragment), both from Celltech;
soluble TNF receptor Type I (Amgen); pegylated soluble TNF receptor
Type I (PEGs TNF-R1) (Amgen); and onercept, a recombinant TNF
binding protein (r-TBP-1) (Serono).
[0051] TNF antagonists suitable for compositions, combination
therapy, co-administration, devices and/or methods of the present
invention (further comprising at least one anti body, specified
portion and variant thereof, of the present invention), include,
but are not limited to, anti-TNF antibodies (e.g., at least one TNF
antagonist (e.g., but not limited to a TNF chemical or protein
antagonist, TNF monoclonal or polyclonal antibody or fragment, a
soluble TNF receptor (e.g., p55, p70 or p85) or fragment, fusion
polypeptides thereof, or a small molecule TNF antagonist, e.g., TNF
binding protein I or II (TBP-1 or TBP-II), nerelimonmab,
infliximab, enteracept (Enbrel.TM.), adalimulab (Humira.TM.),
CDP-571, CDP-870, afelimomab, lenercept, and the like),
antigen-binding fragments thereof, and receptor molecules which
bind specifically to TNF; compounds which prevent and/or inhibit
TNF synthesis, TNF release or its action on target cells, such as
thalidomide, tenidap, phosphodiesterase inhibitors (e.g,
pentoxifylline and rolipram), A2b adenosine receptor agonists and
A2b adenosine receptor enhancers; compounds which prevent and/or
inhibit TNF receptor signaling, such as mitogen activated protein
(MAP) kinase inhibitors; compounds which block and/or inhibit
membrane TNF cleavage, such as metalloproteinase inhibitors;
compounds which block and/or inhibit TNF activity, such as
angiotensin converting enzyme (ACE) inhibitors (e.g., captopril);
and compounds which block and/or inhibit TNF production and/or
synthesis, such as MAP kinase inhibitors.
[0052] As used herein, a "tumor necrosis factor antibody," "TNF
antibody," "TNF.alpha. antibody," or fragment and the like
decreases, blocks, inhibits, abrogates or interferes with
TNF.alpha. activity in vitro, in situ and/or preferably in vivo.
For example, a suitable TNF human antibody of the present invention
can bind TNF.alpha. and includes anti-TNF antibodies,
antigen-binding fragments thereof, and specified mutants or domains
thereof that bind specifically to TNF.alpha.. A suitable TNF
antibody or fragment can also decrease block, abrogate, interfere,
prevent and/or inhibit TNF RNA, DNA or protein synthesis, TNF
release, TNF receptor signaling, membrane TNF cleavage, TNF
activity, TNF production and/or synthesis.
[0053] Chimeric antibody cA2 consists of the antigen binding
variable region of the high-specificity neutralizing mouse
anti-human TNF.alpha. IgG1 antibody, designated A2, and the
constant regions of a human IgG1, kappa immunoglobulin. The human
IgG1 Fc region improves allogeneic antibody effector function,
increases the circulating serum half-life and decreases the
immunogenicity of the antibody. The avidity and epitope specificity
of the chimeric antibody cA2 is derived from the variable region of
the murine antibody A2. In a particular embodiment, a preferred
source for nucleic acids encoding the variable region of the murine
antibody A2 is the A2 hybridoma cell line.
[0054] Chimeric A2 (cA2) neutralizes the cytotoxic effect of both
natural and recombinant human TNF.alpha. in a dose dependent
manner. From binding assays of chimeric antibody cA2 and
recombinant human TNF.alpha., the specificity constant of chimeric
antibody cA2 was calculated to be 1.04.times.10.sup.10M.sup.-1.
Preferred methods for determining monoclonal antibody specificity
and specificity by competitive inhibition can be found in Harlow,
et al., antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, New York, 1988; Colligan et
al., eds., Current Protocols in Immunology, Greene Publishing
Assoc. and Wiley Interscience, New York, (1992-2000); Kozbor et
al., Immunol. Today, 4:72-79 (1983); Ausubel et al., eds. Current
Protocols in Molecular Biology, Wiley Interscience, New York
(1987-2000); and Muller, Meth. Enzymol., 92:589-601 (1983), which
references are entirely incorporated herein by reference.
[0055] In a particular embodiment, murine monoclonal antibody A2 is
produced by a cell line designated c134A. Chimeric antibody cA2 is
produced by a cell line designated c168A.
[0056] Additional examples of monoclonal anti-TNF antibodies that
can be used in the present invention are described in the art (see,
e.g., U.S. Pat. No. 5,231,024; Moller, A. et al., Cytokine
2(3):162-169 (1990); U.S. application Ser. No. 07/943,852 (filed
Sep. 11, 1992); Rathjen et al., International Publication No. WO
91/02078 (published Feb. 21, 1991); Rubin et al., EPO Patent
Publication No. 0 218 868 (published Apr. 22, 1987); Yone et al.,
EPO Patent Publication No. 0 288 088 (Oct. 26, 1988); Liang, et
al., Biochem. Biophys. Res. Comm. 137:847-854 (1986); Meager, et
al., Hybridoma 6:305-311 (1987); Fendly et al., Hybridoma 6:359-369
(1987); Bringman, et al., Hybridoma 6:489-507 (1987); and Hirai, et
al., J. Immunol. Meth. 96:57-62 (1987), which references are
entirely incorporated herein by reference).
[0057] Preferred TNF receptor molecules useful in the present
invention are those that bind TNFa with high specificity (see,
e.g., Feldmann et al., International Publication No. WO 92/07076
(published Apr. 30, 1992); Schall et al., Cell 61:361-370 (1990);
and Loetscher et al., Cell 61:351-359 (1990), which references are
entirely incorporated herein by reference) and optionally possess
low immunogenicity. In particular, the 55 kDa (p55 TNF-R) and the
75 kDa (p75 TNF-R) TNF cell surface receptors are useful in the
present invention. Truncated forms of these receptors, comprising
the extracellular domains (ECD) of the receptors or functional
portions thereof (see, e.g., Corcoran et al., Eur. J. Biochem.
223:831-840 (1994)), are also useful in the present invention.
Truncated forms of the TNF receptors, comprising the ECD, have been
detected in urine and serum as 30 kDa and 40 kDa TNFa inhibitory
binding proteins (Engelmann, H. et al., J. Biol. Chem.
265:1531-1536 (1990)). TNF receptor multimeric molecules and TNF
immunoreceptor fusion molecules, and derivatives and fragments or
portions thereof, are additional examples of TNF receptor molecules
which are useful in the methods and compositions of the present
invention. The TNF receptor molecules which can be used in the
invention are characterized by their ability to treat patients for
extended periods with good to excellent alleviation of symptoms and
low toxicity. Low immunogenicity and/or high specificity, as well
as other undefined properties, can contribute to the therapeutic
results achieved.
[0058] TNF receptor multimeric molecules useful in the present
invention comprise all or a functional portion of the ECD of two or
more TNF receptors linked via one or more polypeptide linkers or
other nonpeptide linkers, such as polyethylene glycol (PEG). The
multimeric molecules can further comprise a signal peptide of a
secreted protein to direct expression of the multimeric molecule.
These multimeric molecules and methods for their production have
been described in U.S. application Ser. No. 08/437,533 (filed May
9, 1995), the content of which is entirely incorporated herein by
reference.
[0059] TNF immunoreceptor fusion molecules useful in the methods
and compositions of the present invention comprise at least one
portion of one or more immunoglobulin molecules and all or a
functional portion of one or more TNF receptors. These
immunoreceptor fusion molecules can be assembled as monomers, or
hetero- or homo-multimers. The immunoreceptor fusion molecules can
also be monovalent or multivalent. An example of such a TNF
immunoreceptor fusion molecule is TNF receptor/IgG fusion protein.
TNF immunoreceptor fusion molecules and methods for their
production have been described in the art (Lesslauer et al., Eur.
J. Immunol. 21:2883-2886 (1991); Ashkenazi et al., Proc. Natl.
Acad. Sci. USA 88:10535-10539 (1991); Peppel et al., J. Exp. Med.
174:1483-1489 (1991); Kolls et al., Proc. Natl. Acad. Sci. USA
91:215-219 (1994); Butler et al., Cytokine 6(6):616-623 (1994);
Baker et al., Eur. J. Immunol. 24:2040-2048 (1994); Beutler et al.,
U.S. Pat. No. 5,447,851; and U.S. application Ser. No. 08/442,133
(filed May 16, 1995), each of which references are entirely
incorporated herein by reference). Methods for producing
immunoreceptor fusion molecules can also be found in Capon et al.,
U.S. Pat. No. 5,116,964; Capon et al., U.S. Pat. No. 5,225,538; and
Capon et al., Nature 337:525-531 (1989), which references are
entirely incorporated herein by reference.
[0060] A functional equivalent, derivative, fragment or region of
TNF receptor molecule refers to the portion of the TNF receptor
molecule, or the portion of the TNF receptor molecule sequence
which encodes TNF receptor molecule, that is of sufficient size and
sequences to functionally resemble TNF receptor molecules that can
be used in the present invention (e.g., bind TNF.alpha. with high
specificity and possess low immunogenicity). A functional
equivalent of TNF receptor molecule also includes modified TNF
receptor molecules that functionally resemble TNF receptor
molecules that can be used in the present invention (e.g., bind
TNF.alpha. with high specificity and possess low immunogenicity).
For example, a functional equivalent of TNF receptor molecule can
contain a "SILENT" codon or one or more amino acid substitutions,
deletions or additions (e.g., substitution of one acidic amino acid
for another acidic amino acid; or substitution of one codon
encoding the same or different hydrophobic amino acid for another
codon encoding a hydrophobic amino acid). See Ausubel et al.,
Current Protocols in Molecular Biology, Greene Publishing Assoc.
and Wiley-Interscience, New York (1987-2003).
[0061] In some embodiments, the monoclonal antibody that inhibits
TNF-a is selected from the group consisting of monoclonal
rodent-human antibodies, rodent antibodies, human antibodies or any
portions thereof, having at least one antigen binding region of an
immunoglobulin variable region, which antibody binds TNF.
Preferably, this monoclonal antibody is selected from the group of
compounds disclosed in U.S. Pat. No. 6,277,969, the specification
of which is incorporated by reference. In some embodiments, the
infliximab is delivered in a formulation having an infliximab
concentration of between about 30 mg/ml and about 60 mg/ml.
[0062] In some embodiments, the specific inhibitor of TNF-a is an
inhibitor of p38 MAP kinase, preferably, a small molecule inhibitor
of p38 MAP kinase. The inhibition of p38 MAP kinase is believed to
block production of both TNF-a and Il-2, both of which are
pro-inflammatory cytokines. The small molecule inhibitors of p38
MAP kinase are very specific & potent (.about.nM). Without
wishing to be tied to a theory, it is believed that inhibition of
p38 should not block TGF signaling nor TGF activity. It is further
believed that p38 inhibitors may also block induction of some
metalloproteinases, COX 2 and NO synthetase. It is further believed
that P38 inhibitors do not inhibit interleukins involved in immune
cell proliferation such as IL-2.
[0063] In some embodiments, the HSCA is a specific antagonist of an
interleukin. Preferably, the target interleukin is selected from
the group consisting IL-1, IL-2, IL-6 and IL-8, and IL-12.
Preferred antagonists include but are not limited to Kineretg
(recombinant IL 1-RA, Amgen), IL1-Receptor Type 2 (Amgen) and IL-1
Trap (Regeneron).
[0064] The present inventors note that DDD involves the progressive
degeneration of a disc in which many factors are involved. In many
of these instances, simply providing a single dose or even a
regimen over the space of a few days may not be sufficient to
resolve the DDD. For example, if DDD were caused in part by
mechanical instability in a functional spinal unit, then simply
providing a one-time therapy for the disc cells will likely only
delay the onset of the DDD. Therefore, there is a need to provide a
long-term drug therapy treatment of DDD that does not require
multiple injections.
[0065] Because it is believed that the cytokines of interest both
produce pain and degrade the ECM when present within the nucleus
pulposus, it is desirable for the HSCA to remain within the nucleus
pulposus as long as possible in a pharmaceutically effective
amount. The half-life of the HSCA within the nucleus pulposus will
depend upon many factors, including the size of the HSCA and its
charge. In general, the larger the molecular weight of the HSCA,
the more likely it is to remain contained by the annulus fibrosus
portion of the disc.
[0066] If the half-life of the HSCA is relatively short, then it
would be desirable for a relatively large dose of the HSCA to be
administered into the disc. In this condition, quick depletion of
the HSCA would not cause the HSCA to fall below therapeutically
effective levels until an extended period.
[0067] Although a large dose of the HSCA would be desirable in such
instances, it is also known that nociceptors present on the inner
wall of the annulus fibrosus react to increased pressure and
produce pain, and that one avenue for increasing the pressure in
the nucleus pulposus is to inject a critical volume of water. In
some cases, the added amount could be as little as one cc by volume
to produce pain. Accordingly, if a dilute concentration of an HSCA
is added to the nucleus pulposus to provide a large dose, the
resulting pressure increase caused by this added volume could be
sufficient to cause acute pain.
[0068] For example, if it were determined that 100 mg of an HSCA
was needed to therapeutically effect a nucleus pulposus, and that
HSCA was provided in concentrations of 30-60 mg/ml, then at least
1.5 ml of the HSCA would need to be injected into the nucleus
pulposus in order to provide the desired therapeutic effect.
However, when injecting volumes into the nucleus pulposus, it is
desirable that the volume of drug delivered be no more than 1 ml,
preferably no more than 0.5 ml, more preferably between 0.1 and 0.3
ml. When injected in these smaller quantities, it is believed the
added volume will not cause an appreciable pressure increase in the
nucleus pulposus.
[0069] In contrast, Olmarker mixed 100 .mu.l of a formulation
comprising only 1.11 mg/ml of a monoclonal antibody into 40 mg of
an extracted nucleus pulposus.
[0070] Accordingly, in some embodiments, the concentration of the
TNF-a antagonist in the administered drug is at least 100 mg/ml.
When 100 mg of the HSCA is needed to produce the desired
therapeutic result, no more than 1 ml of the drug need be injected.
Preferably, the concentration of the TNF-a antagonist in the
administered drug is at least 200 mg/ml. In this condition, no more
than 0.5 ml of the drug need be injected. Preferably, the
concentration of the TNF-a antagonist in the administered drug is
at least 500 mg/ml. In this condition, between 0.03 and 0.3 ml of
the drug need be injected.
[0071] In some embodiments, the HSCA is provided in a sustained
release device. The sustained release device is adapted to remain
within the disc for a prolonged period and slowly release the HSCA
contained therein to the surrounding environment. This mode of
delivery allows an HSCA to remain in therapeutically effective
amounts within the disc for a prolonged period.
[0072] In some embodiments, the HSCA is predominantly released from
the sustained delivery device by its diffusion through the
sustained delivery device (preferably, though a polymer). In
others, the HSCA is predominantly released from the sustained
delivery device by the biodegradation of the sustained delivery
device (preferably, biodegradation of a polymer).
[0073] Preferably, the sustained release device comprises a
bioresorbable material whose gradual erosion causes the gradual
release of the HSCA to the disc environment. In some embodiments,
the sustained release device comprises a bioresorbable polymer.
Preferably, the bioresorbable polymer has a half-life of at least
one month, more preferably at least two months, more preferably at
least 6 months.
[0074] In some embodiments, the sustained release device provides
controlled release. In others, it provides continuous release. In
others, it provides intermittent release. In others, the sustained
release device comprises a biosensor.
[0075] In some embodiments, the sustained delivery device comprises
bioerodable macrospheres. The HSCA is preferably contained in a
gelatin (or water or other solvent) within the capsule, and is
released to the disc environment when the outer shell has been
eroded. The device can include a plurality of capsules having outer
shells of varying thickness, so that the sequential breakdown of
the outer shells provides periodic release of the HSCA.
[0076] In some embodiments, the sustained delivery device comprises
an inflammatory-responsive delivery system, preferably comprising
bioerodable microspheres that are eroded by invading macrophages.
This technology provides a high correspondence between physiologic
inflammation of disc environment and the release of the HSCAs into
that environment. Preferably, the technology disclosed in Brown et
al., Arthritis. Rheum. 1998 December; 41(12) pp., 2185-95 is
selected.
[0077] In some embodiments, the sustained delivery device comprises
the devices disclosed in U.S. Pat. No. 5,728,396 ("Peery"), the
specification of which is incorporated by reference in its
entirety.
[0078] In some embodiments, the sustained delivery device comprises
a plurality (preferably at least one hundred) of water-containing
chambers, each chamber containing the HSCA. Each chamber is defined
by bilayer lipid membranes comprising synthetic duplicates of
naturally occurring lipids. The release of the drug can be
controlled by varying at least one of the aqueous excipients, the
lipid components, and the manufacturing parameters. Preferably, the
formulation comprises no more than 10% lipid. In some embodiments,
the Depofoam.TM. technology of Skyepharma PLC (located in London,
United Kingdom) is selected.
[0079] In some embodiments, the sustained delivery device comprises
a delivery system disclosed in U.S. Pat. No. 5,270,300
("Hunziker"), the specification of which is incorporated by
reference in its entirety.
[0080] In some embodiments, the sustained delivery device comprises
the co-polymer poly-DL-lactide-co-glycolide (PLG). Preferably, the
formulation is manufactured by combining the HSCA, the co-polymer
and a solvent to form a droplet, and then evaporating the solvent
to form a microsphere. The plurality of microspheres are then
combined in a biocompatible diluent. Preferably, the HSCA is
released from the co-polymer by its diffusion therethrough and by
the biodegradation of the co-polymer. In some embodiments hereof,
the ProLease.TM. technology of Alkermes (located in Cambridge,
Mass.) is selected.
[0081] Hydrogels can also be used to deliver the HSCA is a
time-release manner to the disc environment. A "hydrogel" is a
substance formed when an organic polymer (natural or synthetic) is
set or solidified to create a three- dimensional open-lattice
structure that entraps molecules of water or other solution to form
a gel. The solidification can occur, e.g., by aggregation,
coagulation, hydrophobic interactions, or cross-linking. The
hydrogels employed in this invention rapidly solidify to keep the
HSCA at the application site, thereby eliminating undesired
migration from the disc. The hydrogels are also biocompatible,
e.g., not toxic, to cells suspended in the hydrogel.
[0082] A "hydrogel-HSCA composition" is a suspension of a hydrogel
containing desired HSCA. The hydrogel-HSCA composition forms a
uniform distribution of HSCA with a well-defined and precisely
controllable density. Moreover, the hydrogel can support very large
densities of HSCA. In addition, the hydrogel allows diffusion of
nutrients and waste products to, and away from, the HSCA, which
promotes tissue growth.
[0083] Hydrogels suitable for use in the present invention include
water-containing gels, i.e., polymers characterized by
hydrophilicity and insolubility in water. See, for instance,
"Hydrogels", pages 458-459 in Concise Encyclopedia of Polymer
Science and Engineering, Eds. Mark et al., Wiley and Sons, 1990,
the disclosure of which is incorporated herein by reference.
Although their use is optional in the present invention, the
inclusion of hydrogels is highly preferred since they tend to
contribute a number of desirable qualities. By virtue of their
hydrophilic, water-containing nature, hydrogels can:
[0084] a) house viable cells, such as mesenchymal stems cells,
and
[0085] b) assist with load bearing capabilities of the disc.
[0086] In a preferred embodiment, the hydrogel is a fine, powdery
synthetic hydrogel. Suitable hydrogels exhibit an optimal
combination of such properties as compatibility with the matrix
polymer of choice, and biocompatability. The hydrogel can include
any of the following: polysaccharides, proteins, polyphosphazenes,
poly(oxyethylene)-poly(oxypropylene) block polymers,
poly(oxyethylene)-poly(oxypropylene) block polymers of ethylene
diamine, poly(acrylic acids), poly(methacrylic acids), copolymers
of acrylic acid and methacrylic acid, poly(vinyl acetate), and
sulfonated polymers.
[0087] In general, these polymers are at least partially soluble in
aqueous solutions, e.g., water, or aqueous alcohol solutions that
have charged side groups, or a monovalent ionic salt thereof. There
are many examples of polymers with acidic side groups that can be
reacted with cations, e.g., poly(phosphazenes), poly(acrylic
acids), and poly(methacrylic acids). Examples of acidic groups
include carboxylic acid groups, sulfonic acid groups, and
halogenated (preferably fluorinated) alcohol groups. Examples of
polymers with basic side groups that can react with anions are
poly(vinyl amines), poly(vinyl pyridine), and poly(vinyl
imidazole).
[0088] In some embodiments, the sustained delivery device includes
a polymer selected from the group consisting of PLA, PGA, PCL, and
mixtures thereof.
[0089] If the half-life of the HSCA within the disc is relatively
long, then it may be assumed that a relatively small dose of the
HSCA can be administered into the disc. In this condition, the slow
depletion of the HSCA would not cause the HSCA to fall below
therapeutically effective levels in the disc until an extended
period of time has elapsed.
[0090] In some embodiments in which HSCAs have long half-lives
within the disc, the dose administered can be very small.
[0091] For example, if it is believed that an HSCA is effective
when present in the range of 1-10 mg/kg or 1-10 ppm (as is believed
to be the case for the TNF antagonist Remicade.TM.), and since a
typical nucleus pulposus of a disc has a volume of about 3 ml (or 3
cc, or 3 g), then only about 3-30 ug of the HSCA need be
administered to the disc in order to provide a long lasting
effective amount of the drug. As a point of reference, Tobinick
discloses that at least 1 mg of cytokine antagonist should be
administered perispinally in order to cure back pain. Similarly,
Olmarker mixed 100 ml of a formulation comprising 1.11 mg/ml of a
monoclonal antibody into 40 mg of an extracted nucleus pulposus,
thereby producing a monoclonal antibody concentration of about 3
parts per thousand. The smaller amounts available by this route
reduce the chances of deleterious side effects of the HSCA.
[0092] For example, suppose a clinician administered 0.3 ml of 60
mg/ml infliximab into a 2.7 cc disc, thereby producing a infliximab
concentration in the disc of about 6 mg/ml, or 6 parts per
thousand. Without wishing to be tied to a theory, if infliximab has
the same half-life within a nucleus pulposus as it does when
administered systemically (i.e., about 1 week), then the
concentration of infliximab would remain above about 10 ppm for
about 9 weeks. Therefore, if another dose were needed, the
clinician would only need to provide the second dose after about
two months.
[0093] Therefore, in some embodiments, the HSCA is provided in a
dose of less than 1 mg, preferably, less than 0.5 mg, more
preferably, less than 0.1 mg, more preferably less than 0.01 mg.
The smaller amounts available by this route reduce the chances of
deleterious side effects of the HSCA. Preferably, the HSCA provided
in these smaller amounts is a TNF antagonist, more preferably is
infliximab.
[0094] In preferred embodiments, the formulation of the present
invention is administered directly into the disc through the outer
wall of the annulus fibrosus. More preferably, the direct
administration includes depositing the HSCA in the nucleus pulposus
portion of the disc. In this condition, the fibrous nature of the
annulus fibrosus that surrounds the nucleus pulposus will help keep
the HSCA contained within the disc.
[0095] Preferably, the formulation of the present invention is
injected into the disc through a small bore needle. More
preferably, the needle has a bore of 22 gauge or less, so that the
possibilities of producing a herniation are mitigated. More
preferably, the needle has a bore of 24 gauge or less, so that the
possibilities of producing a herniation are even further
mitigated.
[0096] If the volume of the direction injection of the formulation
is sufficiently high so as to cause a concern of overpressurizing
the nucleus pulposus, then it is preferred that at least a portion
of the nucleus pulposus be removed prior to direct injection.
Preferably, the volume of removed nucleus pulposus is substantially
similar to the volume of the formulation to be injected. More
preferably, the volume of removed nucleus pulposus is within
80-120% of the volume of the formulation to be injected. In
addition, this procedure has the added benefit of at least
partially removing some degenerated disc from the patient.
[0097] In other embodiments, the formulation is delivered into the
disc space through the endplate of an opposing vertebral body. This
avenue eliminates the need to puncture the annulus fibrosus, and so
eliminates the possibility of herniation.
[0098] Although the cytokine antagonists may therapeutically treat
the disc by binding the target cytokine, and thereby reducing pain
and arresting degradation of the ECM, it is believed that at least
some of these antagonists do not help repair the damage done by the
cytokine to the ECM.
[0099] Therefore, there may be a need to provide a therapy that
also helps repair the ECM.
[0100] In accordance with the present invention, there is provided
a method of treating degenerative disc disease in an intervertebral
disc having a nucleus pulposus, comprising the steps of:
[0101] a) administering a highly specific cytokine antagonist into
a degenerating disc; and
[0102] b) administering a second therapeutic agent in an amount
effective to at least partially repair the disc.
[0103] In accordance with one aspect of the invention, both the
HSCA and second therapeutic agent are locally administered into the
disc. Because the HSCA is specific, it does not interfere with the
locally administered second therapeutic agent, and so each agent
may independently work to provide therapy to the diseased disc.
[0104] In some embodiments, the HSCA and second therapeutic agent
are administered simultaneously. In others, the HSCA is
administered first. In still others, the second therapeutic agent
is administered first.
[0105] Other compounds which may be added to the disc include, but
are not limited to: vitamins and other nutritional supplements;
hormones; glycoproteins; fibronectin; peptides and proteins;
carbohydrates (both simple and/or complex); proteoglycans;
oligonucleotides (sense and/or antisense DNA and/or RNA); BMPs;
antibodies (for example, to infectious agents, tumors, drugs or
hormones); and gene therapy reagents. Genetically altered cells
and/or other cells may also be included in the matrix of this
invention. If desired, substances such as pain killers and
narcotics may also be admixed with a polymer for delivery and
release to the disc space.
[0106] Preferably, healthy cells are introduced into the disc that
have the capability of at least partially repairing any damage done
to the disc during the degenerative process. In some embodiments,
these cells are introduced into the nucleus pulposus and ultimately
produce new extracellular matrix for the nucleus pulposus. In
others, these cells are introduced into the annulus fibrosus and
produce new extracellular matrix for the annulus fibrosus.
[0107] In some embodiments, these cells are obtained from another
human individual (allograft), while in others, the cells are
obtained from the same individual (autograft). In some embodiments,
the cells are taken from an intervertebral disc (and can be either
nucleus pulposus cells or annulus fibrosus cells), while in others,
the cells are taken from a non-disc tissue (and may be mesenchymal
stem cells). In others, autograft chondrocytes (such as from the
knee, hip, shoulder, finger or ear) may be used.
[0108] Preferably, when viable cells are selected as the second
therapeutic substance, the viable cells comprise mesenchymal stem
cells (MSCs). MSCs provide a special advantage for administration
into a degenerating disc because it is believed that they can more
readily survive the relatively harsh environment present in the
degenerating disc; that they have a desirable level of plasticity;
and that they have the ability to proliferate and differentiate
into the desired cells.
[0109] In some embodiments, the mesenchymal stems cells are
obtained from bone marrow, preferably autologous bone marrow. In
others, the mesenchymal stems cells are obtained from adipose
tissue, preferably autologous adipose tissue.
[0110] In some embodiments, the mesenchymal stem cells injected
into the disc are provided in an unconcentrated form. In others,
they are provided in a concentrated form. When provided in
concentrated form, they are preferably uncultured. Uncultured,
concentrated MSCs can be readily obtained by centrifugation,
filtration, or immuno-absorption. When filtration is selected, the
methods disclosed in U.S. Pat. No. 6,049,026 ("Muschler"), the
specification of which is incorporated by reference in its
entirety, are preferably used. In some preferred embodiments, the
matrix used to filter and concentrate the MSCs is also administered
into the nucleus pulposus. If this matrix has suitable mechanical
properties, it can be used to restore the height of the disc space
that was lost during the degradation process.
[0111] As used herein, the term "growth factors" encompasses any
cellular product that modulates the growth or differentiation of
other cells, particularly connective tissue progenitor cells. The
growth factors that may be used in accordance with the present
invention include, but are not limited to, members of the
fibroblast growth factor family, including acidic and basic
fibroblast growth factor (FGF-1 and -2) and FGF-4, members of the
platelet-derived growth factor (PDGF) family, including PDGF-AB,
PDGF-BB and PDGF-AA; EGFs, members of the insulin-like growth
factor (IGF) family, including IGF-I and -II; the TGF-.beta.
superfamily, including TGF-.beta.1, 2 and 3 (including MP-52),
osteoid-inducing factor (OIF), angiogenin(s), endothelins,
hepatocyte growth factor and keratinocyte growth factor; members of
the bone morphogenetic proteins (BMP's) BMP-1, (BMP-3); BMP-2;
OP-1; BMP-2A, -2B, and -7, BMP-14; HBGF-1 and -2; growth
differentiation factors (GDF's), members of the hedgehog family of
proteins, including indian, sonic and desert hedgehog; ADMP-1;
members of the interleukin (IL) family, including IL-1 thru -6;
GDF-5 and members of the colony-stimulating factor (CSF) family,
including CSF-1, G-CSF, and GM-CSF; and isoforms thereof.
[0112] In some embodiments, the growth factor is selected from the
group consisting of TGF-B, bFGF, and IGF-1. These growth factors
are believed to promote regeneration of the nucleus pulposus.
Preferably, the growth factor is TGF-B. More preferably, TGF-B is
administered in an amount of between 10 ng/ml and 5000 ng/ml, more
preferably between 50 ng/ml and 500 ng/ml, more preferably between
100 ng/ml and 300 ng/ml.
[0113] In some embodiments, platelet concentrate is provided as the
second therapeutic agent. Preferably, the growth factors released
by the platelets are present in an amount at least two-fold (more
preferably, four-fold) greater than the amount found in the blood
from which the platelets were taken. More preferably, the platelet
concentrate is autologous. In some embodiments, the platelet
concentrate is platelet rich plasma (PRP). PRP is advantageous
because it contains growth factors that can restimulate the growth
of the ECM, and because its fibrin matrix provides a suitable
scaffold for new tissue growth.
[0114] Since it is known that many pro-inflammatory proteins play a
role in disc degeneration, and that the antagonists of the present
invention are highly specific, it is further believed that
injecting at least two of the highly specific antagonists of the
present invention directly into the disc would be advantageous.
[0115] Therefore, in accordance with the present invention, there
is provided a method of treating degenerative disc disease in an
intervertebral disc having a nucleus pulposus, comprising the steps
of:
[0116] a) administering a formulation comprising at least two
highly specific antagonists of pro-inflammatory cytokines selected
from the group consisting of TNF-.alpha., an interleukin
(preferably, IL-1, Il-6 and IL-8), FAS, an FAS ligand, and
IFN-gamma.
[0117] Preferably, at least one of the substances is an antagonist
of TNF-a. Preferably, the other substance is an antagonist of an
interleukin.
[0118] In some embodiments, the formulation comprises a suitable
biocompatible carrier such as saline. In some embodiments, the
carrier is selected from the carriers disclosed in U.S. Pat. No.
6,277,969 ("Le"), the specification of which is incorporated by
reference in its entirety.
[0119] Also in accordance with the present invention, there is
provided a formulation for treating degenerative disc disease,
comprising:
[0120] a) a high specificity cytokine antagonist, and
[0121] b) a second therapeutic agent selected from the group
consisting of: [0122] i) a growth factor, and [0123] ii) viable
cells.
[0124] In some embodiments of this formulation, the high
specificity cytokine antagonist is selected from the group
consisting of antagonists of TNF and antagonists of an
interleukin.
[0125] Because the causes of low back pain may be myriad, and
because of the significant cost of many of these specialized HSCAs,
it would be useful for the clinician to first perform a diagnostic
test in order to confirm that the targeted disc in fact possesses
high levels of the targeted cytokine prior to providing the
injection.
[0126] In one embodiment, the diagnostic test comprises a
non-invasive diagnostic test comprising using an MRI.
[0127] Preferably, the clinician would first perform a discogram in
order to identify which disc or discs are responsible for the
patient's low back pain. Next, the clinician would perform an
invasive or non-invasive test upon the targeted disc in order to
confirm the presence of or quantify the level of the
pro-inflammatory cytokine.
[0128] In one embodiment, the diagnostic test comprises an invasive
test in which a portion of the disc is removed and analyzed. In
some embodiments, the clinician removes a portion of the nucleus
pulposus. In others, the clinician removes a portion of the annulus
fibrosus. Preferably, the removed material is a portion of the
nucleus pulposus. The presence of pro-inflammatory cytokines in the
removed material may detected by procedures including but not
limited to electrophoresis, or an enzyme-linked immunoabsorbent
assay (as per Burke, Br. JBJS, 84-B(2), 2002).
[0129] In some embodiments, the diagnostic methods disclosed in
U.S. Pat. No. 6,277,969 ("Le"), the specification of which is
incorporated by reference in its entirety, are selected. In these
methods, high specificity anti-TNF-.alpha. compounds are used as
diagnostic tools for detecting TNF-alpha in the patient known or
suspected to have a high level of TNF-alpha.
[0130] After determining the levels of the different
pro-inflammatory cytokines in the degenerating disc, the clinician
will preferably proceed to compare these diagnosed levels against
pre-determined levels of the pro-inflammatory cytokines. If the
diagnosed level of the pro-inflammatory cytokine exceeds the
pre-determined level, then the clinician may conclude that these
higher levels are causing unwanted inflammatory action and proceed
to directly inject a specific HSCA into the disc capable of
inhibiting the targeted protein.
[0131] In some embodiments, the predetermined level for an
interleukin is at least 100 pg/ml. In some embodiments, the
predetermined level for IL-6 is at least 250 pg/ml. In some
embodiments, the predetermined level for IL-8 is at least 500
pg/ml. In some embodiments, the predetermined level for PGE2 is at
least 1000 pg/ml. In some embodiments, the predetermined level for
TNF-.alpha. is at least 500 pg/ml. In others, the predetermined
level for TNF-.alpha. is at least 20 pg/ml, more preferably at
least 30 pg/ml, more preferably at least 50 pg/ml, more preferably
at least 1 ng/ml. In others, the predetermined level for
TNF-.alpha. is at least 1 ng/disc.
[0132] It would also be useful to be able to determine whether
directly administering the therapeutic substances of the present
invention was in fact efficacious. Accordingly, one can measure the
level of cytokine remaining in the disc after administration.
[0133] It is further believed that the present invention can also
be used to prevent degeneration of an intervertebral disc in a
human individual, namely, by following a procedure comprising the
steps of:
[0134] a) determining a genetic profile of the individual,
[0135] b) comparing the profile of the individual against a
pre-determined genetic profile level of at-risk humans,
[0136] c) determining that the individual is at at-risk patient,
and
[0137] d) injecting an antagonist of the pro-inflammatory protein
into a disc of the individual.
EXAMPLE I
[0138] This non-limiting prophetic example describes how to
transdiscally administer a formulation comprising a HSCA and saline
into a nucleus pulposus of a degenerating disc.
[0139] First, the clinician uses a diagnostic test to verify that a
particular disc within a patient has high levels of a particular
pro-inflammatory cytokine.
[0140] Next, the clinician provides a local anesthetic (such as 5
ml lidocaine) to the region dorsal of the disc of concern to reduce
subcutaneous pain.
[0141] Next, the clinician punctures the skin of the patient dorsal
the disc of concern with a relatively large (e.g., 18-19 gauge)
needle having a stylet therein, and advances the needle through
subcutaneous fat and dorsal sacrolumbar ligament and muscles to the
outer edge of the intervertebral disc.
[0142] Next, the stylet is removed from the needle.
[0143] Next, the clinician receives a syringe having a smaller
gauge needle adapted to fit within the larger gauge needle. This
needle is typically a 22 or 24 gauge needle. The barrel of the
syringe contains the formulation of the present invention.
[0144] The formulation contains infliximab, and has an infliximab
concentration of between about 30 mg/ml and about 60 mg/ml.
[0145] Next, the physician advances the smaller needle co-axially
through the larger needle and past the distal end of the larger
needle, thereby puncturing the annulus fibrosus. The smaller needle
is then further advanced into the center of the nucleus pulposus.
Finally, the clinician depresses the plunger of the syringe,
thereby injecting between about 0.1 and 1 ml of the formulation
into the nucleus pulposus.
EXAMPLE II
[0146] This non-limiting prophetic example is substantially similar
to that of Example I, except that the formulation comprises a
sustained release device comprising the co-polymer
poly-DL-lactide-co-glycolide (PLG). The formulation contains
infliximab as the antagonist, and has an infliximab concentration
of between about 30 mg/ml and about 60 mg/ml.
[0147] While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
* * * * *